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Sarah F. Keller,1 Jennifer L. Kelly,1 Elizabeth Sensenig,2 Jennifer Andreozzi,1 Jamie Oliva,1
Lynn Rich,1 Louis Constine,1 Michael Becker,1 Gordon Phillips,1 Jane Liesveld,1
Richard I. Fisher,1 Steven H. Bernstein,1 Jonathan W. Friedberg1Salvage chemotherapy followed by high-dose autologous stem cell transplantation (HD-ASCT) is the stan-
dard of care for patients who have relapsed or refractory Hodgkin’s lymphoma (HL). Few trials have had
long-term follow-up post-HD-ASCT in the ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine)
era of treatment. We reviewed 95 consecutive patients who received HD-ASCT for relapsed or refractory
HL following ABVD failure between 1990 and 2006 at the University of Rochester. Median follow-up for sur-
vivors was 8.2 years. All patients received HD-ASCT following upfront ABVD (or equivalent) failure. At
5 years, overall survival (OS) and event-free survival (EFS) were 54% and 37%, respectively. In total, 54 patients
have died; 37 of these patients died directly of HL. Notably, there were 19 deaths .3 years post-HD-ASCT
and 13 of these late deaths are directly attributable to HL. Furthermore, there were 51 documented relapses,
9 of which occurred .3 years post-HD-ASCT. In contrast to other studies, we did not observe a plateau in
EFS following transplantation. Patients appear to be at continuous risk of recurrence beyond 3 years after
HD-ASCT. Our results emphasize the importance of long-term follow-up for both toxicity and recurrence,
and have important implications in defining success of posttransplantation maintenance strategies.
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tory disease, HD-ASCTINTRODUCTION
Approximately 80% of patients with advanced-
stage Hodgkin’s lymphoma (HL) achieve a complete
remission when treated with ABVD (adriamycin,
bleomycin, vinblastine, and dacarbazine), the current
gold-standard upfront HL therapy in the United
States, or ABVD/mechlorethamine, vincristine, pro-
carbazine, and prednisone hybrid therapy [1]. Thus,
20% of patients fail primary induction and an addi-
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6/j.bbmt.2011.08.012[1]. High-dose chemotherapy followed by autologous
stem cell transplantation (HD-ASCT) postsalvage
therapy is the standard of care for patients with re-
lapsed or primary refractory HL [2-12].
Early relapses following HD-ASCT in the pre-
ABVD era are well defined in the literature. Indeed,
the majority of HL relapses occur within the first 2
years following HD-ASCT [13-15]. Poor prognostic
factors have been identified, including systemic
symptoms, extranodal disease at relapse, increased
age, increased cycles of pretransplantation regimens,
bulky disease, and poor performance status at
transplantation [7,15-20]. Several studies, however,
have called for systematic examination of long-term
effects and specifically, relapse following HD-ASCT
[10,17]. Long-term complications have been identi-
fied, including mortality associated with infections,
cardiac problems, including myocardial infarction
and cardiomyopathy, and secondary malignancies
[6,14,21-23]. However, very few studies have
exclusively examined late relapses following
autologous transplantation. Although relapse itself
does not necessarily pose an immediate threat to
survival, only a small number of patients who relapse
Biol Blood Marrow Transplant 18:640-647, 2012 641Late Events following HD-ASCTafter HD-ASCT will achieve long-term disease-free
survival [4,12]. The median time to progression
following HD-ASCT is approximately 6 months [24].
Several studies conducted at large transplant centers
have clearly identified a plateau in overall survival
(OS) beginning at 2 years post-HD-ASCT in the pre-
ABVD therapeutic era, implying that HL mortality
after this point is negligible. The Vancouver group’s
landmark 2005 study on the first 100 patients to un-
dergo HD-ASCT at their center, universally viewed
as the paradigm of long-term surveillance posttrans-
plantation, defines a plateau in OS beginning at 2 years
post-HD-ASCT [14].
There is therefore a lack of studies that examine
the long-term outcomes and late relapses of HD-
ASCT following first-line therapy in the modern
ABVD era; additional studies that characterize the
late effects associated with ABVD failure rescued by
HD-ASCT are valuable because ABVD is the current
standard of care for advanced stage HL in the United
States [25]. We analyzed all consecutive patients who
underwent HD-ASCT following ABVD failure at
theUniversity of Rochester from 1990 to 2006 to char-
acterize the long-term outcomes and late effects of
relapsed and refractory HL treated with HD-ASCT
in the ABVD therapeutic era.MATERIALS AND METHODS
Patients
This studywas reviewed and approved by the institu-
tional review board at the University of Rochester Med-
ical Center (URMC). All consecutive patients over the
age of 17 with documented HL who received HD-
ASCT at the URMC James P. Wilmot Cancer Center
between the years 1990 and 2006 following upfront
ABVD therapy or equivalent and who were registered
in the URMC Bone Marrow Transplant Registry were
examined in this study. All patients who underwent
HD-ASCT after either a failure to achieve complete re-
mission or disease relapse following initial ABVD che-
motherapy or equivalent were eligible for inclusion. All
HL diagnoses were confirmed by hematopathology
review at URMC. Disease status was established before
HD-ASCTby the treating physician andwas not reeval-
uated at the time of transplantation. Relapsed and
primary refractory disease before HD-ASCT was con-
firmed by biopsy or imaging. In the event that both com-
puted tomography 6 positron emissions tomography
and biopsy confirmed relapsed disease, the date of biopsy
was taken as thedateof relapse.Patientswere categorized
as primary refractory or induction failure if they had
relapsed\1 year after initial HL diagnosis, first relapse
if they had 1 relapse $1 year after initial diagnosis, and
advanced disease if they had experienced 2 or more HL
relapses at the time of HD-ASCT.Data Collection
The first day of follow-up was defined as the day af-
ter HD-ASCT; follow-up continued until the date of
the most recent medical contact or date of confirmed
death. All data were abstracted through extensive re-
view ofURMCmedical records (including clinical, his-
tologic, laboratory, and diagnostic imaging records),
URMC bone marrow transplant records, outside clinic
charts, physician correspondence, death certificates,
and autopsy reports when available. Data collected in-
cluded: disease characteristics and staging; pre-HD-
ASCT treatment history; salvage, conditioning, and
HD-ASCT regimens; progression of disease; treat-
ments following post-HD-ASCT relapse; secondary
malignancies; vital status; and cause of death (COD).
Information regarding COD and vital status of pa-
tients with prolonged follow-up times was confirmed
via the National Death Index (NDI). Records were
matched according to NDI’s published recommenda-
tions [26,27]. At the time of data collection, NDI
records extended through the year 2006; thus, date
and cause of death for patients with a date of last
contact beyond 2006 was determined solely by our
URMC chart review process. In cases where there
was no URMC COD, the NDI search results were
used exclusively. COD was classified according to
a modified version of the 3-tiered system described
by Lavoie et al. [14] in 2005: progressive HL (includ-
ing treatment-related death from recurrent HL after
HD-ASCT), treatment-related mortality (TRM)
(including organ failure or second malignancy), or
other (death unrelated to HL disease progression or
treatment).Statistical Analysis
Demographic characteristics of the study cohort
were summarized and reported as median values (and
range) for continuous variables, and proportions for
categoric variables. Event-free survival (EFS) was de-
fined as time from HD-ASCT date to relapse or death
from any cause, and patients without an event were cen-
sored at their most recent medical contact. OS was de-
fined as time from the HD-ASCT date to death from
any cause; patients who were still alive at the end of
follow-up were censored as either December 31, 2006
(end of NDI record availability) or their most recent
medical contact if after January 1, 2007. Both EFS
and OS were estimated by standard Kaplan-Meier sur-
vival techniques. We compared OS from the time of
first documented relapse post-HD-ASCT by timing
of relapse (\6 months post-HD-ASCT, excluding
TRM; 6 to 12 months post-HD-ASCT, and .12
months post-HD-ASCT) using the log-rank test. Ex-
pecting that those patients who relapsed within the first
year post-HD-ASCT were going to have an inferior
prognosis, we further evaluated whether or not there
642 Biol Blood Marrow Transplant 18:640-647, 2012S. F. Keller et al.was a difference in OS post-HD-ASCT relapse for
those relapsing 1 to 3 years post-HD-ASCT and those
who relapsed late (defined arbitrarily as.3 years post-
HD-ASCT), although we acknowledge that this
comparison is exploratory because of limited power
to formally test this comparison. Median follow-up
was calculated both based on median time from
HD-ASCT to the censoring date among the living
patients and with the use of the reverse Kaplan-Meier
estimator [28]. Statistical analysis was conducted using
SAS statistical software (SAS Institute, Cary, NC).RESULTS
Patient Characteristics
Ninety-five patients were eligible and are included
in this analysis. Demographic attributes of patients and
therapy details are included in Table 1. The majority
of patients were White (88%) and female (51%). Me-
dian age was 34 years (19-66). Patients predominantly
presented with stage III to IV (53%), nodular scleros-
ing HL (70%), and B symptoms (62%) at the time of
diagnosis. All patients underwent ABVD or ABVD
equivalent therapy. The majority of patients in this
study had chemosensitive disease (78%). MedianTable 1. Patient, Disease, and Transplant Characteristics
Characteristic N 5 95 %
Age (median, range) 34 (19-66)
Female 48 50.5%
Race
White 84 88.4%
Black 7 7.4%
Other 4 4.2%
Hodgkin’s lymphoma histology
Nodular sclerosis 66 69.5%
Mixed cellularity 19 20.0%
Classical NOS 1 1.1%
Lymphocyte predominant 4 4.2%
Lymphocyte depleted 3 3.2%
Unknown 2 2.1%
Disease stage at diagnosis
Early stage (I/II) 43 45.3%
Advanced stage (III/IV) 50 52.6%
B symptoms at diagnosis 59 62.1%
Disease status at transplantation
First relapse 57 60.0%
Primary refractory or induction failure 33 34.7%
Advanced disease 5 5.3%
Chemosensitivity
Chemosensitive 74 77.9%
Conditioning regimen
BEAC 50 52.6%
BEAM 36 37.9%
TBI + cyclophosphamide 9 9.5%
Consolidative radiation therapy 47 49.5%
Graft type
Bone marrow 17 17.9%
Peripheral blood 66 69.5%
Bone marrow + peripheral blood 12 12.6%
NOS indicates not otherwise specified; BEAC, carmustine, etoposide,
cytarabine, and cyclophosphamide; BEAM, carmustine, etoposide,
cytarabine, and melphalan; TBI, total body irradiation.time to HD-ASCT from diagnosis was 1.9 years
(0.7-19.6 years). A greater proportion of patients
(60%) was transplanted in the first relapse.
Treatment and Conditioning Regimens
Patients received 1 of several salvage therapies, in-
cluding dexamethasone, cytarabine, and cisplatin; eto-
poside, methylprednisone, cytarabine, and cisplatin;
ifosfamide, carboplatin, and etoposide; ABVD, etopo-
side, vinblastine, and doxorubicin; bortezomib, and
gemcitabine on a clinical trial [29]; and cyclophospha-
mide, local radiotherapy, and surgical debulking. A
minimum of 2  108 mononuclear cells/kg body
weight from the bone marrow, or 2  106 CD341
cells/kg body weight from the peripheral blood, were
required in order to proceed to autologous transplanta-
tion. Conditioning regimens were carmustine, etopo-
side, cytarabine, and melphalan (38%); carmustine,
etoposide, cytarabine, and cyclophosphamide (53%);
or total body irradiation 1 cyclophosphamide (9%).
Forty-seven patients (49%) also received consolidative
radiotherapy following HD-ASCT.
Post-HD-ASCT
Twenty-nine patients were alive without relapse as
of August 5, 2011. The median follow-up time for
survivors was 8.2 years (1.5-21.2 years), and the
Kaplan-Meier estimated median follow-up was 10.3
years (95% confidence interval, 6.5-11.1 years). Patient
outcomes are summarized in Figure 1, and causes of
death for the 54 observed deaths to date are summarized
in Table 2. Kaplan-Meier estimated EFS and OS at
5 years was 37% and 54%, respectively (Figure 2).
Our central findings is that 19 of the 54 deaths (35%)
occurred more than 3 years after HD-ASCT, and 13
(68% of all late deaths) are directly attributable to HL.
Post-HD-ASCT TRM
In total, 10 deaths of 54 total deaths were attrib-
uted to complications of therapy (TRM defined previ-
ously). Included in this category are 6 deaths within
101 days of transplantation, 2 deaths beyond 101
days because of posttransplantation complications,
and 2 deaths because of secondary malignancy without
evidence of HL progression.
Progression of HL Post-HD-ASCT
We observed documented relapses in 51 patients.
Forty-two relapses occurred within 3 years posttrans-
plantation. However, we observed 9 relapses (18% of
all relapses) beyond 3 years; the disease characteristics
of these late relapse patients are provided in Table 3.
Out of all 51 patients who relapsed, 39 patients have
expired: 37 deaths are because of HL (including
TRM for recurrent HL), 1 death is unrelated to HL,
and 1 death is because of unknown causes. Twelve of
Figure 1. Summary of patient outcomes following HD-ASCT.
Biol Blood Marrow Transplant 18:640-647, 2012 643Late Events following HD-ASCTthe 51 relapsed patients remain alive and many have
received multiple treatment regimens since relapse
post-HD-ASCT: 7 patients were treated with localized
radiotherapy, 5 received additional chemotherapy, 4
received allogeneic transplants (3 have relapsed; 1 is
in remission), 3 were treated with monoclonal anti-
bodies, 2 with Brentuximab vedotin (SGN 35) [30],
and 1 with SGN 30, and 1 patient had a second autol-
ogous transplant. Four of these 12 patients achieved
complete remission: 1 following a second ASCT, 1
following an allogeneic transplantation, 1 following
radiation therapy, and 1 following SGN 30.Death from Progression of HL Post-HD-ASCT
Thirty-seven patients (39%) have died of pro-
gressive HL. Included in progressive HL deaths are
patients who died of treatment-related complicationsTable 2. Causes of Death for N5 54 Patients (Median Follow-
up 5 Years)
Characteristic N 5 54 %
Progressive HL (including TRM for recurrent HL) 37 68.5
Treatment-related mortality 10 18.5
Early deaths (within 101 days of HD-ASCT) 6
Second malignancies 2
Deaths secondary to treatment (>101 days
post-HD-ASCT)*
2
Deaths unrelated to HL 5 9.3
Acute MI 2
Acute cholecystitis 1
Noninfective gastroenteritis/colitis 1
COPD 1
Unknown 2
TRM indicates treatment-related mortality; MI, myocardial infarction;
COPD, chronic obstructive pulmonary disease.
*Pneumothorax (1), infection pneumonitis (1).for recurrent HL.We do observe inferior OS for those
who relapse early in the first year post-HD-ASCT, as
expected (Figure 3A). However, among those who re-
lapse.1 year post-HD-ASCT, the survival experienceFigure 2. Kaplan-Meier estimates of (A) EFS (years; N 5 95); and (B)
OS (years; N 5 95).
Table 3. Characteristics of Late Relapses (Relapse >3 Years Post-HD-ASCT, n 5 9)
Age* Stage† Histology
Conditioning
Regimen Disease Characteristics‡
Post-transplant
Radiation
Consolidation
Event Free
Survival
(years) Survival COD
40 IV B Lymphocyte Predominant BEAC Advanced disease; Chemosensitive No 3.1 Expired TRM
20 II B Nodular Sclerosis BEAC PIF; Chemosensitive Yes 3.1 Expired Unknown
40 II Indeterminate BEAC Chemosensitive No 4.0 Alive
33 IV Mixed cellularity BEAM Chemosensitive No 4.4 Alive
40 III Nodular Sclerosis BEAC Chemosensitive No 4.8 Expired HL
46 IV B Nodular Sclerosis TBI/Cy Chemosensitive Yes 5.1 Alive
39 IV B Nodular Sclerosis BEAM Chemoresistant No 5.1 Alive
44 III Nodular Sclerosis BEAM PIF; Chemosensitive No 5.4 Expired HL
64 II Nodular Sclerosis BEAC Unknown Chemosensitivity Yes 13.1 Expired HL
PIF indicates primary induction failure; COD, cause of death; TRM, treatment-related mortality; BEAC, carmustine, etoposide, cytarabine, and
cyclophosphamide; BEAM, carmustine, etoposide, cytarabine, and melphalan;TBI, total body irradiation; Cy, cyclophosphamide.
*Age at high-dose autologous stem cell transplant.
†Stage at diagnosis.
‡All patients were transplanted after salvage following first relapse unless noted to be primary induction failures or have advanced disease (2 or more
relapses before transplant).
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(defined as .3 years post-HD-ASCT for this study)
compared with those patients who relapse earlier
(1-3 years post-HD-ASCT) (Figure 3B).Figure 3. Kaplan-Meier estimates of (A)OS from time of relapse, strat-
ified by length of time between HD-ASCTand relapse (n5 51 relapses,
n5 6 TRM excluded), log-rank P\.001; and (B) OS from time of relapse
for those that relapsed 1 to 3 years post-HD-ASCT vs those that
relapsed.3 years post-HD-ASCT (n5 26), log-rank P5.93, hazard ra-
tio for OSwith relapse.3 years post-HD-ASCT vsOSwith relapse 1 to
3 years post-HD-ASCT 5 1.05 (95% confidence interval, 0.39-2.77).DISCUSSION
This study examined the long-term outcomes of
patients with relapsed or refractory HL who under-
went HD-ASCT in the ABVD era.We reported a me-
dian follow-up time of 8.2 years. Similar to comparable
studies [13-15,31-34], the majority of our patients
remain alive at 5 years and over one-third are disease
free, emphasizing the continued utility of HD-ASCT.
In contrast to these studies, however, we observed a no-
ticeably higher number of late relapses. In particular,
we observed 9 late relapses $3 years post-HD-
ASCT (18% of total relapses) without a plateau in
either OS or EFS. We also observed 19 late deaths
occurring 3 years post-HD-ASCT; 13 of these late
deaths are directly attributed to HL. Although the
3-year post-HD-ASCT threshold for defining late
relapses and late deaths is somewhat arbitrary, our ex-
perience demonstrates a clear, continual risk of late re-
lapse and HL-related mortality following HD-ASCT.
Most notably, our threshold is even later than the
2-year OS plateau identified in large cohort series,
such as the Vancouver study and the Cleveland Clinic
Taussig Cancer Institute/Memorial Sloa-Kettering
Cancer Center study, underscoring the finding that
there is no plateau in OS. We did observe, however,
a similar survival experience following HD-ASCT re-
lapse when comparing those whom we designated as
late relapse (.3 years post-HD-ASCT) to those who
relapsed earlier (1-3 years post-HD-ASCT).
There are several potential explanations for the
late relapses observed in this study. We have examined
long-term HD-ASCT in the post-ABVD therapeutic
era, and suggest that the use of ABVD has important
ramifications for our observed results. The majority
of studies that have examined HD-ASCT outcomes
in relapsed HL (summarized in Table 4) did so draw-
ing heavily on data from the early 1990s before upfront
ABVD therapy or equivalent was established
Table 4. Comparison of Studies Examining Long-Term Outcomes after HD-ASCT for Relapsed/Refractory HL
Author Date
Study
Duration N % ABVD R/P
Median f/u
Time (Years) % EFS % OS Comment
Bierman 2002 1984-1999 379 NS R 5.1 24 (10 years) 32 (10 years)
Stiff 2003 1990-1995 74 14 P 10 41 (5 years) 54 (5 years) No late events in sensitive* patients; some
late events in resistant† patients
Moskowitz 2004 1985-1998 75 81.3 P 10 45 (10 years) 48 (10 years) OS, EFS plateau
Lavoie 2005 1985-1992 100 NS P 11.4 51 (15 years) 54 (15 years) OS plateau
Majhail 2006 1985-2003 141 63.8 R 6.3 48 (5 years) 53 (5 years) OS plateau, some late events
Sirohi 2008 1985-2005 195 NS P 10.3 44 (5 years) 55 (5 years)
Smith 2011 1995-2008 214 82.7 R 6 45 55 Study limited to early relapses; EFS plateau
URMC 2011 1990-2006 95 100 R 8.2 37 (5 years) 54 (5 years) Notable late events
NS indicates not specified; R, retrospective study; P, prospective study; sensitive*, chemosensitive disease; resistant†, chemoresistant disease.
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vanced HL in the United States [1,15,25,35-38]. Our
data differs substantially from previous experiences in
the pre-ABVD therapeutic era and potentially suggests
that the natural history of HL after HD-ASCT follow-
ing upfront ABVD therapymay differ from the historic
experience of mechlorethamine, vincristine, procarba-
zine, and prednisone. This finding may have further
implications when even more aggressive induction
therapies, such as BEACOPP-escalated, are used
[39,40]. In addition, our findings might be explained
by the rigorous methods used to track patients
following HD-ASCT. Larger clinical investigations
might not employ such aggressive follow-up to pa-
tients.3 years removed from autologous transplanta-
tion. This explanation would suggest that late relapses
occur, but are not captured by the majority of studies;
thus, the current body of literature might be underre-
porting the true incidence of late relapses following
HD-ASCT. Last, it is possible that we observed an
increased number of late relapses because our ‘‘real-
world’’ patient population was not selected for favor-
able prognostic features. The majority of the clinical
trial literature examines HD-ASCT outcomes of a se-
lected group of relatively young patients with favorable
prognostic features. Many of the patients in our series
had prognostically unfavorable characteristics at diag-
nosis, including B symptoms (62%) and advanced
stage (III/IV) HL (53%). In addition, 33 patients in
our series (35%) were primary induction failures, and
5 patients (5%) had advanced disease. Interestingly,
the majority of our patients had chemosensitive disease
(78%), and only 1 of our late relapses had documented
chemoresistance. Comparable studies often include
a highly selected patient population, with additional
cardiac, pulmonary, renal, and hepatic function inclu-
sion criteria. We submit that late events and relapses
detailed in our series might be more applicable to the
average HL patient, with relapsed or refractory disease
requiring aggressive treatment encountered in a clinic
setting.
With a median follow-up time of 8.2 years, we
demonstrated a substantial number of relapses and
deaths $3 years post-HD-ASCT. Clinicians need tobe aware that HL patients remain at a continued risk
of relapse, in addition to the well-documented risk of
late therapy-related toxicity. Based on our results,
HL patients may benefit from close monitoring post-
transplantation, perhaps for at least 5 to 10 years after
HD-ASCT. Furthermore, our results emphasize
the potential role for novel therapeutic approaches
currently under evaluation to improve HD-ASCT
outcomes, including maintenance approaches with
therapeutic agents such as Brentuximab vedotin, antic-
ipated to receive U.S. Food and Drug Administration
approval, as well as with intensive, double HD-ASCT
[30,41-44]. Reduced-intensity allogeneic transplanta-
tion might yield lasting remission in those patients
who fail HD-ASCT, while limiting toxic exposure.
In addition, consolidative radiotherapy following
autologous transplantation was shown in the 2003
Southwest Oncology Group study to improve out-
comes following HD-ASCT and should be considered
as a potential strategy to maximize response in high-
risk patients or those with refractory disease [34].
Moreover, given that late relapse is a reality following
HD-ASCT in the ABVD era, the long natural history
of HL has significant implications on endpoints for
clinical trials of novel conditioning regimens before
autologous transplantation, as well as maintenance
strategies post-HD-ASCT.ACKNOWLEDGMENTS
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